Endeavor BioMedicines Reports Results from the P-IIa Study of ENV-101 for Treating Idiopathic Pulmonary Fibrosis
Shots:
- The P-IIa study assesses the safety & efficacy of ENV-101 (200mg, QD) vs PBO to treat idiopathic pulmonary fibrosis patients (n=41) for 12wks.
- The study showed a 1.9% vs 1.3% mean improvement in ppFVC, a 200mL increase in total lung capacity among 80% of patients vs 56mL decrease in 70% of them, reduced quantitative interstitial lung disease (QILD) by 9.4% vs 1.1% increase, quantitative lung fibrosis (QLF) by 2% vs 0.87% increase & quantitative ground glass (QGG) by 4.6% vs 0.29% increase
- Based on presented data, the company to initiate P-II (WHISTLE-PF) study having a global P-IIb IPF arm & a parallel P-II progressive pulmonary fibrosis (PPF) arm, for which the company has secured $132.5M Series C funding
Ref: Aileron Therapeutics |Image: Aileron Therapeutics
Related News:- Aileron Therapeutics Reports Cohort 1 Results from the P-Ib Study of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
